

What is claimed is:

- 5  
10  
15  
20  
25  
30  
35
1. A method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT<sub>1F</sub> receptor agonist which activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates each of the human 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, and 5-HT<sub>7</sub> receptors.
2. The method of claim 1, wherein the 5-HT<sub>1F</sub> receptor agonist additionally activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates each of the 5-HT<sub>1B</sub>, 5-HT<sub>1E</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>5A</sub>, 5-HT<sub>5B</sub>, and 5-HT<sub>6</sub> receptors.
3. The method of claim 1, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates any human  $\alpha_2$  adrenoceptor or any human  $\beta$  adrenoceptor.
4. The method of claim 1, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human histamine H<sub>1</sub> and H<sub>2</sub> receptors.
5. The method of claim 1, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, and D<sub>5</sub> receptors.
6. The method of claim 1, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it

activates the human  $\alpha_{1A}$  adrenoceptor and the human  $\alpha_{1B}$  adrenoceptor.

- 5        7.    The method of claim 1, wherein the 5-HT<sub>1F</sub> receptor agonist activates the human 5-HT<sub>1F</sub> receptor at least 50-fold more than it activates each of the human 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, and 5-HT<sub>7</sub> receptors.
- 10      8.    The method of claim 7, wherein the 5-HT<sub>1F</sub> receptor agonist additionally activates the human 5-HT<sub>1F</sub> receptor at least 50-fold more than it activates each of the human 5-HT<sub>1B</sub>, 5-HT<sub>1E</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>5A</sub>, 5-HT<sub>5B</sub>, and 5-HT<sub>6</sub> receptors.
- 15      9.    The method of claim 7, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates any human  $\alpha_2$  adrenoceptor or any human
- 20       $\beta$  adrenoceptor.
- 25      10.   The method of claim 7, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human histamine H<sub>1</sub> and H<sub>2</sub> receptors.
- 30      11.   The method of claim 7, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, and D<sub>5</sub> receptors.
- 35      12.   The method of claim 7, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human  $\alpha_{1A}$  adrenoceptor and the human  $\alpha_{1B}$  adrenoceptor.

13. The method of claim 7, wherein the 5-HT<sub>1F</sub> receptor agonist activates the human 5-HT<sub>1F</sub> receptor at least 100-fold more than it  
5 activates each of the human 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, and 5-HT<sub>7</sub> receptors.
14. The method of claim 13, wherein the 5-HT<sub>1F</sub> receptor agonist additionally activates the  
10 human 5-HT<sub>1F</sub> receptor at least 100-fold more than it activates each of the human 5-HT<sub>1B</sub>, 5-HT<sub>1E</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>5A</sub>, 5-HT<sub>5B</sub>, and 5-HT<sub>6</sub> receptors.
15. The method of claim 13, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it  
15 activates any human  $\alpha_2$  adrenoceptor or any human  $\beta$  adrenoceptor.
16. The method of claim 13, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it  
20 activates the human histamine H<sub>1</sub> and H<sub>2</sub> receptors.
17. The method of claim 13, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it  
25 activates the human dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, and D<sub>5</sub> receptors.
18. The method of claim 13, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it  
30 activates the human  $\alpha_{1A}$  adrenoceptor and the human  $\alpha_{1B}$  adrenoceptor.
- 35

19. The method of claim 13, wherein the 5-HT<sub>1F</sub> receptor agonist activates the human 5-HT<sub>1F</sub> receptor at least 200-fold more than it activates each of the human 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, and 5-HT<sub>7</sub> receptors.
20. The method of claim 19, wherein the 5-HT<sub>1F</sub> receptor agonist additionally activates the human 5-HT<sub>1F</sub> receptor at least 200-fold more than it activates each of the human 5-HT<sub>1B</sub>, 5-HT<sub>1E</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>5A</sub>, 5-HT<sub>5B</sub>, and 5-HT<sub>6</sub> receptors.
21. The method of claim 19, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates any human  $\alpha_2$  adrenoceptor or any human  $\beta$  adrenoceptor.
22. The method of claim 19, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human histamine H<sub>1</sub> and H<sub>2</sub> receptors.
23. The method of claim 19, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, and D<sub>5</sub> receptors.
24. The method of claim 19, wherein the 5-HT<sub>1F</sub> receptor agonist also activates the human 5-HT<sub>1F</sub> receptor at least ten-fold more than it activates the human  $\alpha_{1A}$  adrenoceptor and the human  $\alpha_{1B}$  adrenoceptor.